*Sponsored by Lifewater Media. Please see disclosures below. |
| "CERO" Teams Up With Top Cancer Center |
| | | | | Hey Folks, CERo Therapeutics (CERO) just announced that its Phase 1 trial for CER-1236, a new treatment for aggressive leukemia, will include a major site at the Colorado Blood Cancer Institute. This move signals strong clinical support for CERO's technology, which uses a unique approach called chimeric engulfment receptor (CER) therapy. Patient enrollment has already started, and first dosing is expected by June, setting the stage for fast-moving trial updates. The study targets hard-to-treat AML patients, including those with the TP53 mutation, and aims to test both safety and early signs of effectiveness. If the trial shows promise, it could quickly position CERo as a serious player in the next wave of cancer therapies. Anyways...
That's all for now! Until Next Time, -Damian | P.S. Want our text alerts? Text "ZIPTRADER" to 1-(855)-228-1598 to sign up!
(standard carrier data/text rates apply) |
|
|
|---|
|
*Sponsored by Lifewater Media. Please see disclosures below. |
|
|---|
|
| | 5101 SANTA MONICA BLVD STE 8 #62, 90029, LOS ANGELES, CA |
| You've received it because you've subscribed to our newsletter or are a member of ZipTraderU. |
| This email was sent to indra21poetra@gmail.com |
| *SPONSORED CONTENT* ZipTrader LLC is a publishing company, we are not financial advisors. This is not financial advice. Investments involve risk and are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance. ZipTrader has been compensated seventeen thousand five hundred USD by ACH Bank Transfer by Lifewater Media to distribute media via email and SMS for CERo Therapeutics Holdings, Inc. (CERO) from April 23, 2025 to April 24, 2025. ZipTrader may receive additional campaigns in the future by Lifewater Media to distribute media for CERo Therapeutics Holdings, Inc. (CERO). As a result of this advertisement and other marketing efforts, ZipTrader may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of ZipTrader do not hold a position in CERo Therapeutics Holdings, Inc. (CERO). This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of CERo Therapeutics Holdings, Inc. (CERO), increased trading volume, and possibly an increased share price of CERo Therapeutics Holdings, Inc. (CERO), which may or may not be temporary and decrease once the marketing arrangement has ended. |
| BY READING THIS EMAIL & ALL ZIPTRADER CONTENT YOU AGREE: This is not financial advice. You must do your own due diligence on all information. ZIPTRADER LLC is a publishing company and we provide general information, opinions, & news coverage to viewers. However – we do not provide personalized financial advice, are not financial advisors, and our opinions are not suitable for all investors. You should not treat any opinion as expressed as a specific inducement to make a particular investment or follow a particular strategy, but just as an opinion. Use at your own risk. Past Performance is not indicative of future results, and any results presented are not typical, and should not be understood as typical. Actual results vary given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. TRADING IS RISKY: Most traders in all markets lose all of their money (and more if they use margin). Most small businesses fail. Do NOT partake in trading, investing, entrepreneurship or any other risky endeavor covered here if you are not prepared with the reality that most fail. We reserve the right to have affiliate relationships with advertisers/sponsors. See Full Terms of Service.See Our Advertisement/Sponsored Stock Disclaimer. |
| | |
|
|
|---|
|
|
|
Tidak ada komentar:
Posting Komentar